Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.87−0.15 (-0.94%)
Close on Nov 18, 2026Market cap $2.96BP/E –Yield –
Dyne Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Dyne Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$480.43M. For fiscal 2025 it was -$405.13M. The highest annual figure on record is -$13.48M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$405.13M | – |
| FY2024 | Dec 31, 2024 | -$294.75M | – |
| FY2023 | Dec 31, 2023 | -$188.89M | – |
| FY2022 | Dec 31, 2022 | -$156.71M | – |
| FY2021 | Dec 31, 2021 | -$123.18M | – |
| FY2020 | Dec 31, 2020 | -$47.67M | – |
| FY2019 | Dec 31, 2019 | -$13.48M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$131.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$145.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$112.32M | – |
| Q3 FY2025 | Sep 30, 2025 | -$91.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$94.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$106.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$85.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$74.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$78.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$43.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$31.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$52.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -$27.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.50M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.75M | – |
See a number that looks wrong?